Regenerative Medicine Market by Product (Stem Cell [Autologous, Allogenic], Immunotherapy, Gene Therapy, Tissue Engineering), Application (Musculoskeletal, Cancer, Dermatology, Wound care, Cardiovascular Diseases, Eye Disorders) - Global Forecast to 2028
The global regenerative medicines market is projected to reach USD 49.0 Billion by 2028 from USD 16.0 Billion in 2023, at a CAGR of 25.1% during the forecast period of 2023 to 2028. Factors such as the wide scope in new therapeutic areas and collaborations and partnerships by major market players are predicted to uplift the market in the coming years. Additionally, rise in the focus of personalized medicine and rising regenerative medicine regulatory approvals will provide lucrative market growth. However, lack of long-term data and ethical and legal concerns and high cost of treatments are predicted to restrict the market.
“The cell therapy segment held the dominant share in the regenerative medicine market.”
Based on product, the global regenerative medicine market is segmented into gene therapy, cell therapy (stem cell therapy [cell transplantations, stem cell therapy products {autologous therapy, allogenic therapy] cell-based immunotherapy products), and tissue engineering products. The increasing popularity of stem therapy is expected to drive the expansion of the cell therapy market.
“Musculoskeletal disorders segment accounted for the largest share of the therapeutic area segment in 2022.”
Based on therapeutic area, the regenerative medicine market is segmented into oncology, musculoskeletal disorders, neurology, ophthalmology, dermatology & wound care, cardiovascular diseases, and other applications. This can be attributed to the increasing preavalence of orthopedic disorders and growing interest on musculoskeletal regeneration research.
“APAC region is likely to grow at a faster pace.”
The regenerative medicine market is segmented into North America, Europe, Asia Pacific, Latin America, Middle East and Africa. APAC region is anticipated to grow at a significant CAGR during the forecast period. High burden of chronic diseases, growing per capita income, and the rising demand for new technologies are expected to support regenerative medicine market growth in the region.
The primary interviews conducted for this report can be categorized as follows:
This report provides a detailed picture of the regenerative medicine market. It aims to estimate the size and future growth potential of the market across different segments, such as product, therapeutic area and region. The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.
Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall regenerative medicine market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.
The report provides insights on the following pointers:
“The cell therapy segment held the dominant share in the regenerative medicine market.”
Based on product, the global regenerative medicine market is segmented into gene therapy, cell therapy (stem cell therapy [cell transplantations, stem cell therapy products {autologous therapy, allogenic therapy] cell-based immunotherapy products), and tissue engineering products. The increasing popularity of stem therapy is expected to drive the expansion of the cell therapy market.
“Musculoskeletal disorders segment accounted for the largest share of the therapeutic area segment in 2022.”
Based on therapeutic area, the regenerative medicine market is segmented into oncology, musculoskeletal disorders, neurology, ophthalmology, dermatology & wound care, cardiovascular diseases, and other applications. This can be attributed to the increasing preavalence of orthopedic disorders and growing interest on musculoskeletal regeneration research.
“APAC region is likely to grow at a faster pace.”
The regenerative medicine market is segmented into North America, Europe, Asia Pacific, Latin America, Middle East and Africa. APAC region is anticipated to grow at a significant CAGR during the forecast period. High burden of chronic diseases, growing per capita income, and the rising demand for new technologies are expected to support regenerative medicine market growth in the region.
The primary interviews conducted for this report can be categorized as follows:
- By Respondent: Supply Side- 80%, and Demand Side - 20%
- By Designation (Supply Side): Managers - 45%, CXOs & Directors - 30%, Executives- 25%
- By Region: North America -55%, Europe -10%, Asia-Pacific -20%, Latin America -10%, MEA- 5%
- Novartis AG (Switzerland)
- Biogen, Inc. (US)
- Sarepta Therapeutics, Inc. (US)
- Gilead Sciences, Inc. (US)
- Amgen Inc. (US)
- Smith+Nephew (UK)
- MEDIPOST Co., Ltd. (Korea)
- JCR Pharmaceuticals Co., Ltd. (Japan)
- Takeda Pharmaceutical Company Limited (Japan)
- CORESTEM, Inc (South Korea)
- Vericel Corporation (US)
- MIMEDX Group, Inc. (US)
- Organogenesis Inc. (US)
- Medtronic (Ireland)
- Bristol-Myers Squibb Company (US)
- Orthocell Ltd. (Australia)
- Mesoblast Ltd. (Australia)
- BioRestorative Therapies, Inc. (US)
- Pluristem Therapeutics Inc. (US)
- TEGOSCIENCE (South Korea)
- ANTEROGEN.CO.,LTD. (South Korea)
- Bluebird bio, Inc. (US)
- Stempeutics Research Pvt Ltd. (India)
- Sibiono GeneTech Co. Ltd. (China)
- Aspect Biosystems Ltd. (Canada)
- Athersys, Inc. (US)
This report provides a detailed picture of the regenerative medicine market. It aims to estimate the size and future growth potential of the market across different segments, such as product, therapeutic area and region. The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.
Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall regenerative medicine market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.
The report provides insights on the following pointers:
- Analysis of key drivers (Growing focus on personalized medicine, steep rise of regulatory approvals in regenerative medicine, rising collaborations and partnerships by major market players, increasing scope in new therapeutic areas), restraints (Lack of long-term data, Ethical and legal concerns and high cost of treatments), opportunities (Integration with artificial intelligence and big data, Harnessing the potential of 3D printing, Growing number of organ transplants) and challenges (Lack of favorable reimbursement policies across various regions) are influencing the growth of regenerative medicine market.
- Product Development/Innovation: Detailed insights on newly launched products of the regenerative medicine market.
- Market Development: Comprehensive information about lucrative markets – the report analyses the regenerative medicine market across varied regions.
- Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the regenerative medicine market.
- Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players include Novartis AG (Switzerland), Biogen, Inc. (US), Sarepta Therapeutics, Inc. (US), Gilead Sciences, Inc. (US), Amgen Inc. (US), Smith+Nephew (UK), MEDIPOST Co., Ltd. (Korea), JCR Pharmaceuticals Co., Ltd. (Japan), Takeda Pharmaceutical Company Limited (Japan) and CORESTEM, Inc (South Korea) and among others in the regenerative medicine market.
1 INTRODUCTION
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS & EXCLUSIONS
1.3 MARKET SCOPE
1.3.1 MARKETS COVERED
1.3.2 YEARS CONSIDERED
1.3.3 CURRENCY CONSIDERED
1.4 RESEARCH LIMITATIONS
1.5 STAKEHOLDERS
1.6 SUMMARY OF CHANGES
1.7 IMPACT OF RECESSION ON REGENERATIVE MEDICINE MARKET
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
FIGURE 1 RESEARCH DESIGN
2.1.1 SECONDARY DATA
2.1.2 PRIMARY DATA
FIGURE 2 BREAKDOWN OF PRIMARIES: REGENERATIVE MEDICINE MARKET
2.2 MARKET SIZE ESTIMATION
FIGURE 3 MARKET SIZE ESTIMATION FOR SUPPLY-SIDE ANALYSIS: REGENERATIVE MEDICINE MARKET, 2022
FIGURE 4 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS, 2022
FIGURE 5 NOVARTIS AG: REVENUE SHARE ANALYSIS, 2022
FIGURE 6 PRODUCT-BASED REVENUE ANALYSIS, 2022
2.2.1 PRIMARY INSIGHTS
FIGURE 7 VALIDATION FROM PRIMARY EXPERTS
2.2.2 SEGMENT ASSESSMENT METHODOLOGY: REGENERATIVE MEDICINE MARKET
FIGURE 8 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
FIGURE 9 CAGR PROJECTIONS: REGENERATIVE MEDICINE MARKET
FIGURE 10 GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, CHALLENGES, AND OPPORTUNITIES IN REGENERATIVE MEDICINE MARKET
2.3 MARKET BREAKDOWN & DATA TRIANGULATION
FIGURE 11 DATA TRIANGULATION METHODOLOGY
2.4 STUDY ASSUMPTIONS
2.5 RISK ANALYSIS
2.6 IMPACT OF RECESSION ON REGENERATIVE MEDICINE MARKET
TABLE 1 GLOBAL INFLATION RATE PROJECTION, 2024–2028 (% GROWTH)
TABLE 2 US HEALTH EXPENDITURE, 2019–2022 (USD MILLION)
TABLE 3 US HEALTH EXPENDITURE, 2023–2027 (USD MILLION)
3 EXECUTIVE SUMMARY
FIGURE 12 REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2023 VS. 2028 (USD MILLION)
FIGURE 13 REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2023 VS. 2028 (USD MILLION)
FIGURE 14 GEOGRAPHICAL SNAPSHOT OF REGENERATIVE MEDICINE MARKET
4 PREMIUM INSIGHTS
4.1 REGENERATIVE MEDICINE MARKET OVERVIEW
FIGURE 15 FOCUS ON PERSONALISED MEDICINE TO DRIVE MARKET GROWTH
4.2 NORTH AMERICA: REGENERATIVE MEDICINE MARKET
FIGURE 16 CELL THERAPY TO COMMAND LARGEST SHARE OF NORTH AMERICAN REGENERATIVE MEDICINE MARKET
4.3 REGENERATIVE MEDICINE MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
FIGURE 17 CHINA TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 18 REGENERATIVE MEDICINE MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
5.2.1 DRIVERS
5.2.1.1 Growing focus on personalized medicine
FIGURE 19 PERCENTAGE OF FDA APPROVALS FOR PERSONALIZED MEDICINE PRODUCTS (2018–2022)
5.2.1.2 Emerging applications in new therapeutic areas
TABLE 4 REGENERATIVE MEDICINE MARKET: EMERGING APPLICATIONS
5.2.1.3 Increasing collaborations and partnerships by major market players
5.2.1.4 Increasing regulatory approvals in regenerative medicine
TABLE 5 LIST OF KEY PRODUCT APPROVALS IN REGENERATIVE MEDICINE MARKET, 2021–2023
5.2.2 RESTRAINTS
5.2.2.1 Lack of long-term data
5.2.2.2 Ethical and legal concerns and high cost of treatments
5.2.3 OPPORTUNITIES
5.2.3.1 Harnessing the potential of 3D printing
5.2.3.2 Integration with artificial intelligence and big data
5.2.3.3 Growing number of organ transplants
5.2.4 CHALLENGES
5.2.4.1 Lack of favorable reimbursement policies across various regions
5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
FIGURE 20 REVENUE SHIFT TOWARD REGENERATIVE MEDICINE COMPANIES
5.4 PRICING ANALYSIS
5.4.1 AVERAGE SELLING PRICE TREND OF KEY PLAYERS, BY PRODUCT
TABLE 6 REGENERATIVE MEDICINE PRICE TREND
5.5 SUPPLY CHAIN ANALYSIS
FIGURE 21 SUPPLY CHAIN ANALYSIS: REGENERATIVE MEDICINE MARKET
5.6 VALUE CHAIN ANALYSIS
FIGURE 22 VALUE CHAIN ANALYSIS: REGENERATIVE MEDICINE MARKET
5.7 ECOSYSTEM ANALYSIS
FIGURE 23 REGENERATIVE MEDICINE MARKET: ECOSYSTEM ANALYSIS
TABLE 7 ROLE IN ECOSYSTEM
5.8 TECHNOLOGY ANALYSIS
FIGURE 24 KEY STEPS IN GENE THERAPY
TABLE 8 STEM CELL THERAPIES AND GENE THERAPIES
5.9 PATENT ANALYSIS
TABLE 9 REGENERATIVE MEDICINE MARKET: INDICATIVE LIST OF PATENTS
5.10 KEY CONFERENCES & EVENTS IN 2024–2025
5.10.1 REGENERATIVE MEDICINE CONFERENCES IN 2024–2025
TABLE 10 REGENERATIVE MEDICINE CONFERENCES IN 2024–2025
5.11 TARIFF & REGULATORY LANDSCAPE
5.11.1 FDA APPROVALS
5.11.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 11 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 12 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 13 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 14 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.12 PORTER’S FIVE FORCES ANALYSIS
TABLE 15 REGENERATIVE MEDICINE MARKET: PORTER’S FIVE FORCES ANALYSIS
5.12.1 THREAT OF NEW ENTRANTS
5.12.2 THREAT OF SUBSTITUTES
5.12.3 BARGAINING POWER OF BUYERS
5.12.4 BARGAINING POWER OF SUPPLIERS
5.12.5 DEGREE OF COMPETITION
5.13 KEY STAKEHOLDERS & BUYING CRITERIA
5.13.1 KEY STAKEHOLDERS IN BUYING PROCESS
FIGURE 25 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF REGENERATIVE MEDICINE PRODUCTS
5.13.2 BUYING CRITERIA FOR REGENERATIVE MEDICINE PRODUCTS
FIGURE 26 KEY BUYING CRITERIA FOR END USERS
5.14 PIPELINE ANALYSIS
TABLE 16 GENE THERAPY PRODUCTS UNDER CLINICAL TRIAL
TABLE 17 CELL THERAPY PRODUCTS UNDER CLINICAL TRIAL
6 REGENERATIVE MEDICINE MARKET, BY PRODUCT
6.1 INTRODUCTION
TABLE 18 REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
6.2 CELL THERAPY
TABLE 19 REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)
TABLE 20 REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY REGION, 2021–2028 (USD MILLION)
TABLE 21 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 22 EUROPE: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 23 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 24 LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY COUNTRY, 2021–2028 (USD MILLION)
6.2.1 STEM CELL THERAPY
TABLE 25 REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)
TABLE 26 REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY REGION, 2021–2028 (USD MILLION)
TABLE 27 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 28 EUROPE: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 29 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 30 LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY COUNTRY, 2021–2028 (USD MILLION)
6.2.1.1 Cell transplantations
6.2.1.1.1 Potential of Allo-SCT in treating AML to drive segmental growth
TABLE 31 REGENERATIVE MEDICINE MARKET FOR CELL TRANSPLANTATIONS, BY REGION, 2021–2028 (USD MILLION)
TABLE 32 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR CELL TRANSPLANTATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 33 EUROPE: REGENERATIVE MEDICINE MARKET FOR CELL TRANSPLANTATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 34 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR CELL TRANSPLANTATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 35 LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR CELL TRANSPLANTATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
6.2.1.2 Stem cell therapy products
TABLE 36 REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 37 REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY REGION, 2021–2028 (USD MILLION)
TABLE 38 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 39 EUROPE: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 40 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 41 LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY COUNTRY, 2021–2028 (USD MILLION)
6.2.1.2.1 Autologous therapy
6.2.1.2.1.1 Low risk of post-treatment complications to support segment growth
TABLE 42 REGENERATIVE MEDICINE MARKET FOR AUTOLOGOUS THERAPY, BY REGION, 2021–2028 (USD MILLION)
TABLE 43 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR AUTOLOGOUS THERAPY, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 44 EUROPE: REGENERATIVE MEDICINE MARKET FOR AUTOLOGOUS THERAPY, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 45 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR AUTOLOGOUS THERAPY, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 46 LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR AUTOLOGOUS THERAPY, BY COUNTRY, 2021–2028 (USD MILLION)
6.2.1.2.2 Allogeneic therapy
6.2.1.2.2.1 High potential in disease treatment to ensure demand and development
TABLE 47 REGENERATIVE MEDICINE MARKET FOR ALLOGENEIC THERAPY, BY REGION, 2021–2028 (USD MILLION)
TABLE 48 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR ALLOGENEIC THERAPY, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 49 EUROPE: REGENERATIVE MEDICINE MARKET FOR ALLOGENEIC THERAPY, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 50 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR ALLOGENEIC THERAPY, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 51 LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR ALLOGENEIC THERAPY, BY COUNTRY, 2021–2028 (USD MILLION)
6.2.2 CELL-BASED IMMUNOTHERAPY
6.2.2.1 Growing adoption of T-cell therapy in cancer treatment to support market growth
TABLE 52 REGENERATIVE MEDICINE MARKET FOR CELL-BASED IMMUNOTHERAPY, BY REGION, 2021–2028 (USD MILLION)
TABLE 53 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR CELL-BASED IMMUNOTHERAPY, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 54 EUROPE: REGENERATIVE MEDICINE MARKET FOR CELL-BASED IMMUNOTHERAPY, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 55 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR CELL-BASED IMMUNOTHERAPY, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 56 LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR CELL-BASED IMMUNOTHERAPY, BY COUNTRY, 2021–2028 (USD MILLION)
6.3 GENE THERAPY
6.3.1 STRONG PRODUCT PIPELINE DUE TO BROADENING APPLICATIONS IN DISEASE TREATMENT TO DRIVE MARKET
TABLE 57 APPROVED GENE THERAPIES, 2022
TABLE 58 REGENERATIVE MEDICINE MARKET FOR GENE THERAPY, BY REGION, 2021–2028 (USD MILLION)
TABLE 59 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR GENE THERAPY, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 60 EUROPE: REGENERATIVE MEDICINE MARKET FOR GENE THERAPY, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 61 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR GENE THERAPY, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 62 LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR GENE THERAPY, BY COUNTRY, 2021–2028 (USD MILLION)
6.4 TISSUE ENGINEERING
6.4.1 HIGH DEMAND FOR TISSUE ENGINEERING PRODUCTS IN DERMATOLOGY & WOUND CARE APPLICATIONS TO DRIVE MARKET
TABLE 63 REGENERATIVE MEDICINE MARKET FOR TISSUE ENGINEERING, BY REGION, 2021–2028 (USD MILLION)
TABLE 64 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR TISSUE ENGINEERING, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 65 EUROPE: REGENERATIVE MEDICINE MARKET FOR TISSUE ENGINEERING, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 66 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR TISSUE ENGINEERING, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 67 LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR TISSUE ENGINEERING, BY COUNTRY, 2021–2028 (USD MILLION)
7 REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA
7.1 INTRODUCTION
TABLE 68 NUMBER OF CLINICAL TRIALS FOR REGENERATIVE MEDICINE PRODUCTS, BY THERAPEUTIC AREA, 2021 VS. 2022
TABLE 69 REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
7.2 ONCOLOGY
7.2.1 INCREASING STEM CELL TRANSPLANTS TO DRIVE MARKET
TABLE 70 INDICATIVE LIST OF COMMERCIALIZED REGENERATIVE CELL THERAPIES FOR ONCOLOGY APPLICATIONS
TABLE 71 REGENERATIVE MEDICINE MARKET FOR ONCOLOGY, BY REGION, 2021–2028 (USD MILLION)
TABLE 72 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR ONCOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 73 EUROPE: REGENERATIVE MEDICINE MARKET FOR ONCOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 74 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR ONCOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 75 LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR ONCOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
7.3 MUSCULOSKELETAL DISORDERS
7.3.1 RISING RESEARCH ON MUSCULOSKELETAL REGENERATION AND PREVALENCE OF ORTHOPEDIC DISORDERS TO DRIVE MARKET
TABLE 76 REGENERATIVE MEDICINE MARKET FOR MUSCULOSKELETAL DISORDERS, BY REGION, 2021–2028 (USD MILLION)
TABLE 77 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR MUSCULOSKELETAL DISORDERS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 78 EUROPE: REGENERATIVE MEDICINE MARKET FOR MUSCULOSKELETAL DISORDERS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 79 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR MUSCULOSKELETAL DISORDERS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 80 LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR MUSCULOSKELETAL DISORDERS, BY COUNTRY, 2021–2028 (USD MILLION)
7.4 DERMATOLOGY & WOUND CARE
7.4.1 RISING USE OF WOUND CARE BIOLOGICS TO DRIVE MARKET
TABLE 81 INDICATIVE LIST OF REGENERATIVE MEDICINE PRODUCTS COMMERCIALIZED FOR TREATMENT OF ACUTE & CHRONIC WOUNDS
TABLE 82 REGENERATIVE MEDICINE MARKET FOR DERMATOLOGY & WOUND CARE, BY REGION, 2021–2028 (USD MILLION)
TABLE 83 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR DERMATOLOGY & WOUND CARE, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 84 EUROPE: REGENERATIVE MEDICINE MARKET FOR DERMATOLOGY & WOUND CARE, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 85 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR DERMATOLOGY & WOUND CARE, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 86 LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR DERMATOLOGY & WOUND CARE, BY COUNTRY, 2021–2028 (USD MILLION)
7.5 CARDIOVASCULAR DISEASES
7.5.1 INCREASING USE OF MSCS FOR CLINICAL RESEARCH ON IHD TO SUPPORT MARKET GROWTH
TABLE 87 REGENERATIVE MEDICINE MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2021–2028 (USD MILLION)
TABLE 88 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 89 EUROPE: REGENERATIVE MEDICINE MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 90 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 91 LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)
7.6 OPHTHALMOLOGY
7.6.1 REGENERATION OF EYE TISSUES FOR AMD TO SUPPORT MARKET GROWTH
TABLE 92 LIST OF PIPELINE PRODUCTS FOR REGENERATIVE MEDICINE IN OPHTHALMOLOGY
TABLE 93 REGENERATIVE MEDICINE MARKET FOR OPHTHALMOLOGY, BY REGION, 2021–2028 (USD MILLION)
TABLE 94 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR OPHTHALMOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 95 EUROPE: REGENERATIVE MEDICINE MARKET FOR OPHTHALMOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 96 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR OPHTHALMOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 97 LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR OPHTHALMOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
7.7 NEUROLOGY
7.7.1 GROWING NUMBER OF GENE THERAPY PRODUCTS APPROVED FOR NEUROLOGICAL DISEASE TREATMENT TO DRIVE MARKET GROWTH
TABLE 98 REGENERATIVE MEDICINE MARKET FOR NEUROLOGY, BY REGION, 2021–2028 (USD MILLION)
TABLE 99 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR NEUROLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 100 EUROPE: REGENERATIVE MEDICINE MARKET FOR NEUROLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 101 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR NEUROLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 102 LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR NEUROLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
7.8 OTHER THERAPEUTIC AREAS
TABLE 103 REGENERATIVE MEDICINE MARKET FOR OTHER THERAPEUTIC AREAS, BY REGION, 2021–2028 (USD MILLION)
TABLE 104 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 105 EUROPE: REGENERATIVE MEDICINE MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 106 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 107 LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2021–2028 (USD MILLION)
8 REGENERATIVE MEDICINE MARKET, BY REGION
8.1 INTRODUCTION
FIGURE 27 NUMBER OF PLAYERS IN REGENERATIVE MEDICINE MARKET, BY REGION, 2020–2022
TABLE 108 NUMBER OF CLINICAL TRIALS FOR REGENERATIVE MEDICINE (2022)
TABLE 109 REGENERATIVE MEDICINE MARKET, BY REGION, 2021–2028 (USD MILLION)
8.2 NORTH AMERICA
FIGURE 28 NORTH AMERICA: REGENERATIVE MEDICINE MARKET SNAPSHOT
TABLE 110 NORTH AMERICA: REGENERATIVE MEDICINE MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 111 NORTH AMERICA: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 112 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)
TABLE 113 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)
TABLE 114 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 115 NORTH AMERICA: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
8.2.1 US
8.2.1.1 Rising number of pipeline products for regenerative medicine to drive market
TABLE 116 US: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 117 US: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)
TABLE 118 US: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)
TABLE 119 US: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 120 US: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
8.2.2 CANADA
8.2.2.1 Rising government initiatives for regenerative medicine research to drive market
TABLE 121 CANADA: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 122 CANADA: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)
TABLE 123 CANADA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)
TABLE 124 CANADA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 125 CANADA: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
8.2.3 NORTH AMERICA: RECESSION IMPACT
8.3 EUROPE
TABLE 126 EUROPE: REGENERATIVE MEDICINE MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 127 EUROPE: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 128 EUROPE: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)
TABLE 129 EUROPE: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)
TABLE 130 EUROPE: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 131 EUROPE: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
8.3.1 GERMANY
8.3.1.1 Rising focus on clinical research and patent approvals to drive market
TABLE 132 GERMANY: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 133 GERMANY: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)
TABLE 134 GERMANY: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)
TABLE 135 GERMANY: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 136 GERMANY: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
8.3.2 UK
8.3.2.1 Incorporating regenerative medicine into commercial healthcare services under NHS to drive market
TABLE 137 UK: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 138 UK: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)
TABLE 139 UK: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)
TABLE 140 UK: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 141 UK: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
8.3.3 FRANCE
8.3.3.1 Structured regulatory framework to drive regenerative medicine product pipeline
TABLE 142 FRANCE: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 143 FRANCE: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)
TABLE 144 FRANCE: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)
TABLE 145 FRANCE: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 146 FRANCE: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
8.3.4 ITALY
8.3.4.1 Rising prevalence of neurological and cardiovascular disorders to drive market
TABLE 147 ITALY: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 148 ITALY: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)
TABLE 149 ITALY: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)
TABLE 150 ITALY: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 151 ITALY: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
8.3.5 SPAIN
8.3.5.1 Favorable regulatory environment to drive product pipeline
TABLE 152 SPAIN: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 153 SPAIN: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)
TABLE 154 SPAIN: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)
TABLE 155 SPAIN: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 156 SPAIN: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
8.3.6 REST OF EUROPE
TABLE 157 REST OF EUROPE: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 158 REST OF EUROPE: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)
TABLE 159 REST OF EUROPE: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)
TABLE 160 REST OF EUROPE: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 161 REST OF EUROPE: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
8.3.7 EUROPE: RECESSION IMPACT
8.4 ASIA PACIFIC
FIGURE 29 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET SNAPSHOT
TABLE 162 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 163 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 164 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)
TABLE 165 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)
TABLE 166 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 167 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
8.4.1 CHINA
8.4.1.1 Favorable government support for development of regenerative medicine to drive market
TABLE 168 CHINA: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 169 CHINA: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)
TABLE 170 CHINA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)
TABLE 171 CHINA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 172 CHINA: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
8.4.2 JAPAN
8.4.2.1 Regulatory amendments to pharmaceutical legislation to drive commercialization of therapies
TABLE 173 JAPAN: REGENERATIVE MEDICINE MARKET, BY PRODUCT,
2021–2028 (USD MILLION)
TABLE 174 JAPAN: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)
TABLE 175 JAPAN: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)
TABLE 176 JAPAN: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 177 JAPAN: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA,
2021–2028 (USD MILLION)
8.4.3 INDIA
8.4.3.1 Introduction of novel therapies for CVD and cancer to support market growth
TABLE 178 INDIA: REGENERATIVE MEDICINE MARKET, BY PRODUCT,
2021–2028 (USD MILLION)
TABLE 179 INDIA: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)
TABLE 180 INDIA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)
TABLE 181 INDIA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 182 INDIA: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
8.4.4 SOUTH KOREA
8.4.4.1 Strong research base and availability of funds to support market growth
TABLE 183 SOUTH KOREA: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 184 SOUTH KOREA: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)
TABLE 185 SOUTH KOREA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)
TABLE 186 SOUTH KOREA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 187 SOUTH KOREA: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
8.4.5 AUSTRALIA
8.4.5.1 Increasing incidence of sports injuries to support market growth
TABLE 188 AUSTRALIA: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 189 AUSTRALIA: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)
TABLE 190 AUSTRALIA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)
TABLE 191 AUSTRALIA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 192 AUSTRALIA: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
8.4.6 REST OF ASIA PACIFIC
TABLE 193 REST OF ASIA PACIFIC: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 194 REST OF ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)
TABLE 195 REST OF ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)
TABLE 196 REST OF ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 197 REST OF ASIA PACIFIC: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
8.4.7 ASIA PACIFIC: RECESSION IMPACT
8.5 LATIN AMERICA
TABLE 198 LATIN AMERICA: REGENERATIVE MEDICINE MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 199 LATIN AMERICA: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 200 LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)
TABLE 201 LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)
TABLE 202 LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 203 LATIN AMERICA: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
8.5.1 BRAZIL
8.5.1.1 Gradual increase in pharmaceutical R&D to support market growth
TABLE 204 BRAZIL: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 205 BRAZIL: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)
TABLE 206 BRAZIL: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)
TABLE 207 BRAZIL: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 208 BRAZIL: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
8.5.2 REST OF LATIN AMERICA
TABLE 209 REST OF LATIN AMERICA: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 210 REST OF LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)
TABLE 211 REST OF LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)
TABLE 212 REST OF LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 213 REST OF LATIN AMERICA: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
8.5.3 LATIN AMERICA: RECESSION IMPACT
8.6 MIDDLE EAST
8.6.1 GROWING FOCUS ON GENETIC MEDICINE DEVELOPMENT PROJECTS TO DRIVE MARKET GROWTH IN COMING YEARS
TABLE 214 MIDDLE EAST: REGENERATIVE MEDICINE MARKET, BY PRODUCT,
2021–2028 (USD MILLION)
TABLE 215 MIDDLE EAST: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)
TABLE 216 MIDDLE EAST: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)
TABLE 217 MIDDLE EAST: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 218 MIDDLE EAST: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
8.6.2 MIDDLE EAST: RECESSION IMPACT
8.7 AFRICA
8.7.1 GROWING COLLABORATIONS TO SUPPORT GROWTH IN COMING YEARS
TABLE 219 AFRICA: REGENERATIVE MEDICINE MARKET, BY PRODUCT,
2021–2028 (USD MILLION)
TABLE 220 AFRICA: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)
TABLE 221 AFRICA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY,
BY TYPE, 2021–2028 (USD MILLION)
TABLE 222 AFRICA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 223 AFRICA: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
8.7.2 AFRICA: RECESSION IMPACT
9 COMPETITIVE LANDSCAPE
9.1 INTRODUCTION
9.2 RIGHT-TO-WIN APPROACHES ADOPTED BY KEY PLAYERS
TABLE 224 REGENERATIVE MEDICINE MARKET: STRATEGIES ADOPTED BY KEY PLAYERS
9.3 REVENUE SHARE ANALYSIS
FIGURE 30 REVENUE ANALYSIS OF KEY PLAYERS (2020–2022)
9.4 MARKET SHARE ANALYSIS
FIGURE 31 MARKET SHARE ANALYSIS OF KEY PLAYERS (2022)
TABLE 225 REGENERATIVE MEDICINE MARKET: DEGREE OF COMPETITION
9.5 COMPANY EVALUATION MATRIX
9.5.1 STARS
9.5.2 EMERGING LEADERS
9.5.3 PERVASIVE PLAYERS
9.5.4 PARTICIPANTS
FIGURE 32 REGENERATIVE MEDICINE MARKET: COMPANY EVALUATION MATRIX, 2022
9.5.5 COMPANY FOOTPRINT ANALYSIS
TABLE 226 REGENERATIVE MEDICINE MARKET: PRODUCT FOOTPRINT ANALYSIS OF KEY PLAYERS
TABLE 227 REGENERATIVE MEDICINE MARKET: REGIONAL FOOTPRINT ANALYSIS OF KEY PLAYERS
9.6 START-UP/SME EVALUATION MATRIX
9.6.1 PROGRESSIVE COMPANIES
9.6.2 RESPONSIVE COMPANIES
9.6.3 DYNAMIC COMPANIES
9.6.4 STARTING BLOCKS
FIGURE 33 REGENERATIVE MEDICINE MARKET: START-UP/SME EVALUATION MATRIX, 2022
9.6.5 COMPETITIVE BENCHMARKING
TABLE 228 REGENERATIVE MEDICINE MARKET: DETAILED LIST OF KEY START-UP/SME PLAYERS
TABLE 229 REGENERATIVE MEDICINE MARKET: COMPETITIVE BENCHMARKING OF START-UP/SME PLAYERS
9.7 COMPETITIVE SCENARIO & TRENDS
9.7.1 PRODUCT LAUNCHES
TABLE 230 REGENERATIVE MEDICINE MARKET: PRODUCT APPROVALS/LAUNCHES, JANUARY 2020 TO DECEMBER 2023
9.7.2 DEALS
TABLE 231 REGENERATIVE MEDICINE MARKET: DEALS, JANUARY 2020 TO DECEMBER 2023
9.7.3 OTHER DEVELOPMENTS
TABLE 232 REGENERATIVE MEDICINE MARKET: OTHER DEVELOPMENTS, JANUARY 2020 TO DECEMBER 2023
10 COMPANY PROFILES
10.1 KEY MARKET PLAYERS
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
10.1.1 NOVARTIS AG
TABLE 233 NOVARTIS AG: COMPANY OVERVIEW
FIGURE 34 NOVARTIS AG: COMPANY SNAPSHOT (2022)
10.1.2 BIOGEN INC.
TABLE 234 BIOGEN INC.: COMPANY OVERVIEW
FIGURE 35 BIOGEN INC.: COMPANY SNAPSHOT (2022)
10.1.3 GILEAD SCIENCES, INC.
TABLE 235 GILEAD SCIENCES, INC.: COMPANY OVERVIEW
FIGURE 36 GILEAD SCIENCES, INC.: COMPANY SNAPSHOT (2022)
10.1.4 SAREPTA THERAPEUTICS, INC.
TABLE 236 SAREPTA THERAPEUTICS, INC.: COMPANY OVERVIEW
FIGURE 37 SAREPTA THERAPEUTICS: COMPANY SNAPSHOT (2022)
10.1.5 AMGEN, INC.
TABLE 237 AMGEN, INC.: COMPANY OVERVIEW
FIGURE 38 AMGEN, INC.: COMPANY SNAPSHOT (2022)
10.1.6 SMITH+NEPHEW
TABLE 238 SMITH+NEPHEW: COMPANY OVERVIEW
FIGURE 39 SMITH+NEPHEW: COMPANY SNAPSHOT (2022)
10.1.7 MEDIPOST CO., LTD.
TABLE 239 MEDIPOST CO., LTD.: COMPANY OVERVIEW
FIGURE 40 MEDIPOST CO., LTD.: COMPANY SNAPSHOT
10.1.8 JCR PHARMACEUTICALS CO., LTD.
TABLE 240 JCR PHARMACEUTICALS CO., LTD.: COMPANY OVERVIEW
FIGURE 41 JCR PHARMACEUTICALS CO., LTD.: COMPANY SNAPSHOT (2022)
10.1.9 TAKEDA PHARMACEUTICAL COMPANY LIMITED
TABLE 241 TAKEDA PHARMACEUTICAL COMPANY LIMITED: COMPANY OVERVIEW
FIGURE 42 TAKEDA PHARMACEUTICAL COMPANY LIMITED: COMPANY SNAPSHOT (2022)
10.1.10 CORESTEM, INC.
TABLE 242 CORESTEM, INC.: COMPANY OVERVIEW
FIGURE 43 CORESTEM, INC.: COMPANY SNAPSHOT (2021)
10.1.11 VERICEL CORPORATION
TABLE 243 VERICEL CORPORATION: COMPANY OVERVIEW
FIGURE 44 VERICEL CORPORATION: COMPANY SNAPSHOT (2022)
10.1.12 MIMEDX GROUP, INC.
TABLE 244 MIMEDX GROUP, INC.: COMPANY OVERVIEW
FIGURE 45 MIMEDX GROUP, INC.: COMPANY SNAPSHOT (2022)
10.1.13 ORGANOGENESIS INC.
TABLE 245 ORGANOGENESIS INC.: COMPANY OVERVIEW
FIGURE 46 ORGANOGENESIS INC.: COMPANY SNAPSHOT (2022)
10.1.14 MEDTRONIC
TABLE 246 MEDTRONIC: COMPANY OVERVIEW
FIGURE 47 MEDTRONIC: COMPANY SNAPSHOT (2022)
10.1.15 BRISTOL-MYERS SQUIBB COMPANY
TABLE 247 BRISTOL-MYERS SQUIBB COMPANY: COMPANY OVERVIEW
FIGURE 48 BRISTOL-MYERS SQUIBB COMPANY: COMPANY SNAPSHOT (2022)
10.2 OTHER PLAYERS
10.2.1 ORTHOCELL LTD.
TABLE 248 ORTHOCELL LTD.: COMPANY OVERVIEW
10.2.2 MESOBLAST LTD.
TABLE 249 MESOBLAST LTD.: COMPANY OVERVIEW
10.2.3 BIORESTORATIVE THERAPIES, INC.
TABLE 250 BIORESTORATIVE THERAPIES, INC.: COMPANY OVERVIEW
10.2.4 PLURISTEM THERAPEUTICS INC.
TABLE 251 PLURISTEM THERAPEUTICS INC.: COMPANY OVERVIEW
10.2.5 TEGOSCIENCE
TABLE 252 TEGOSCIENCE: COMPANY OVERVIEW
10.2.6 ANTEROGEN.CO.,LTD.
TABLE 253 ANTEROGEN.CO.,LTD.: COMPANY OVERVIEW
10.2.7 BLUEBIRD BIO, INC.
TABLE 254 BLUEBIRD BIO, INC.: COMPANY OVERVIEW
10.2.8 STEMPEUTICS RESEARCH PVT. LTD.
TABLE 255 STEMPEUTICS RESEARCH PVT. LTD.: COMPANY OVERVIEW
10.2.9 SIBIONO GENETECH CO. LTD.
TABLE 256 SIBIONO GENETECH CO. LTD.: COMPANY OVERVIEW
10.2.10 ASPECT BIOSYSTEMS
TABLE 257 ASPECT BIOSYSTEMS: COMPANY OVERVIEW
TABLE 258 ATHERSYS, INC.: COMPANY OVERVIEW
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
11 APPENDIX
11.1 DISCUSSION GUIDE
11.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
11.3 CUSTOMIZATION OPTIONS
11.4 RELATED REPORTS
11.5 AUTHOR DETAILS
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS & EXCLUSIONS
1.3 MARKET SCOPE
1.3.1 MARKETS COVERED
1.3.2 YEARS CONSIDERED
1.3.3 CURRENCY CONSIDERED
1.4 RESEARCH LIMITATIONS
1.5 STAKEHOLDERS
1.6 SUMMARY OF CHANGES
1.7 IMPACT OF RECESSION ON REGENERATIVE MEDICINE MARKET
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
FIGURE 1 RESEARCH DESIGN
2.1.1 SECONDARY DATA
2.1.2 PRIMARY DATA
FIGURE 2 BREAKDOWN OF PRIMARIES: REGENERATIVE MEDICINE MARKET
2.2 MARKET SIZE ESTIMATION
FIGURE 3 MARKET SIZE ESTIMATION FOR SUPPLY-SIDE ANALYSIS: REGENERATIVE MEDICINE MARKET, 2022
FIGURE 4 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS, 2022
FIGURE 5 NOVARTIS AG: REVENUE SHARE ANALYSIS, 2022
FIGURE 6 PRODUCT-BASED REVENUE ANALYSIS, 2022
2.2.1 PRIMARY INSIGHTS
FIGURE 7 VALIDATION FROM PRIMARY EXPERTS
2.2.2 SEGMENT ASSESSMENT METHODOLOGY: REGENERATIVE MEDICINE MARKET
FIGURE 8 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
FIGURE 9 CAGR PROJECTIONS: REGENERATIVE MEDICINE MARKET
FIGURE 10 GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, CHALLENGES, AND OPPORTUNITIES IN REGENERATIVE MEDICINE MARKET
2.3 MARKET BREAKDOWN & DATA TRIANGULATION
FIGURE 11 DATA TRIANGULATION METHODOLOGY
2.4 STUDY ASSUMPTIONS
2.5 RISK ANALYSIS
2.6 IMPACT OF RECESSION ON REGENERATIVE MEDICINE MARKET
TABLE 1 GLOBAL INFLATION RATE PROJECTION, 2024–2028 (% GROWTH)
TABLE 2 US HEALTH EXPENDITURE, 2019–2022 (USD MILLION)
TABLE 3 US HEALTH EXPENDITURE, 2023–2027 (USD MILLION)
3 EXECUTIVE SUMMARY
FIGURE 12 REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2023 VS. 2028 (USD MILLION)
FIGURE 13 REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2023 VS. 2028 (USD MILLION)
FIGURE 14 GEOGRAPHICAL SNAPSHOT OF REGENERATIVE MEDICINE MARKET
4 PREMIUM INSIGHTS
4.1 REGENERATIVE MEDICINE MARKET OVERVIEW
FIGURE 15 FOCUS ON PERSONALISED MEDICINE TO DRIVE MARKET GROWTH
4.2 NORTH AMERICA: REGENERATIVE MEDICINE MARKET
FIGURE 16 CELL THERAPY TO COMMAND LARGEST SHARE OF NORTH AMERICAN REGENERATIVE MEDICINE MARKET
4.3 REGENERATIVE MEDICINE MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
FIGURE 17 CHINA TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 18 REGENERATIVE MEDICINE MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
5.2.1 DRIVERS
5.2.1.1 Growing focus on personalized medicine
FIGURE 19 PERCENTAGE OF FDA APPROVALS FOR PERSONALIZED MEDICINE PRODUCTS (2018–2022)
5.2.1.2 Emerging applications in new therapeutic areas
TABLE 4 REGENERATIVE MEDICINE MARKET: EMERGING APPLICATIONS
5.2.1.3 Increasing collaborations and partnerships by major market players
5.2.1.4 Increasing regulatory approvals in regenerative medicine
TABLE 5 LIST OF KEY PRODUCT APPROVALS IN REGENERATIVE MEDICINE MARKET, 2021–2023
5.2.2 RESTRAINTS
5.2.2.1 Lack of long-term data
5.2.2.2 Ethical and legal concerns and high cost of treatments
5.2.3 OPPORTUNITIES
5.2.3.1 Harnessing the potential of 3D printing
5.2.3.2 Integration with artificial intelligence and big data
5.2.3.3 Growing number of organ transplants
5.2.4 CHALLENGES
5.2.4.1 Lack of favorable reimbursement policies across various regions
5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
FIGURE 20 REVENUE SHIFT TOWARD REGENERATIVE MEDICINE COMPANIES
5.4 PRICING ANALYSIS
5.4.1 AVERAGE SELLING PRICE TREND OF KEY PLAYERS, BY PRODUCT
TABLE 6 REGENERATIVE MEDICINE PRICE TREND
5.5 SUPPLY CHAIN ANALYSIS
FIGURE 21 SUPPLY CHAIN ANALYSIS: REGENERATIVE MEDICINE MARKET
5.6 VALUE CHAIN ANALYSIS
FIGURE 22 VALUE CHAIN ANALYSIS: REGENERATIVE MEDICINE MARKET
5.7 ECOSYSTEM ANALYSIS
FIGURE 23 REGENERATIVE MEDICINE MARKET: ECOSYSTEM ANALYSIS
TABLE 7 ROLE IN ECOSYSTEM
5.8 TECHNOLOGY ANALYSIS
FIGURE 24 KEY STEPS IN GENE THERAPY
TABLE 8 STEM CELL THERAPIES AND GENE THERAPIES
5.9 PATENT ANALYSIS
TABLE 9 REGENERATIVE MEDICINE MARKET: INDICATIVE LIST OF PATENTS
5.10 KEY CONFERENCES & EVENTS IN 2024–2025
5.10.1 REGENERATIVE MEDICINE CONFERENCES IN 2024–2025
TABLE 10 REGENERATIVE MEDICINE CONFERENCES IN 2024–2025
5.11 TARIFF & REGULATORY LANDSCAPE
5.11.1 FDA APPROVALS
5.11.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 11 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 12 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 13 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 14 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.12 PORTER’S FIVE FORCES ANALYSIS
TABLE 15 REGENERATIVE MEDICINE MARKET: PORTER’S FIVE FORCES ANALYSIS
5.12.1 THREAT OF NEW ENTRANTS
5.12.2 THREAT OF SUBSTITUTES
5.12.3 BARGAINING POWER OF BUYERS
5.12.4 BARGAINING POWER OF SUPPLIERS
5.12.5 DEGREE OF COMPETITION
5.13 KEY STAKEHOLDERS & BUYING CRITERIA
5.13.1 KEY STAKEHOLDERS IN BUYING PROCESS
FIGURE 25 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF REGENERATIVE MEDICINE PRODUCTS
5.13.2 BUYING CRITERIA FOR REGENERATIVE MEDICINE PRODUCTS
FIGURE 26 KEY BUYING CRITERIA FOR END USERS
5.14 PIPELINE ANALYSIS
TABLE 16 GENE THERAPY PRODUCTS UNDER CLINICAL TRIAL
TABLE 17 CELL THERAPY PRODUCTS UNDER CLINICAL TRIAL
6 REGENERATIVE MEDICINE MARKET, BY PRODUCT
6.1 INTRODUCTION
TABLE 18 REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
6.2 CELL THERAPY
TABLE 19 REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)
TABLE 20 REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY REGION, 2021–2028 (USD MILLION)
TABLE 21 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 22 EUROPE: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 23 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 24 LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY COUNTRY, 2021–2028 (USD MILLION)
6.2.1 STEM CELL THERAPY
TABLE 25 REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)
TABLE 26 REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY REGION, 2021–2028 (USD MILLION)
TABLE 27 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 28 EUROPE: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 29 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 30 LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY COUNTRY, 2021–2028 (USD MILLION)
6.2.1.1 Cell transplantations
6.2.1.1.1 Potential of Allo-SCT in treating AML to drive segmental growth
TABLE 31 REGENERATIVE MEDICINE MARKET FOR CELL TRANSPLANTATIONS, BY REGION, 2021–2028 (USD MILLION)
TABLE 32 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR CELL TRANSPLANTATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 33 EUROPE: REGENERATIVE MEDICINE MARKET FOR CELL TRANSPLANTATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 34 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR CELL TRANSPLANTATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 35 LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR CELL TRANSPLANTATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
6.2.1.2 Stem cell therapy products
TABLE 36 REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 37 REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY REGION, 2021–2028 (USD MILLION)
TABLE 38 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 39 EUROPE: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 40 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 41 LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY COUNTRY, 2021–2028 (USD MILLION)
6.2.1.2.1 Autologous therapy
6.2.1.2.1.1 Low risk of post-treatment complications to support segment growth
TABLE 42 REGENERATIVE MEDICINE MARKET FOR AUTOLOGOUS THERAPY, BY REGION, 2021–2028 (USD MILLION)
TABLE 43 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR AUTOLOGOUS THERAPY, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 44 EUROPE: REGENERATIVE MEDICINE MARKET FOR AUTOLOGOUS THERAPY, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 45 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR AUTOLOGOUS THERAPY, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 46 LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR AUTOLOGOUS THERAPY, BY COUNTRY, 2021–2028 (USD MILLION)
6.2.1.2.2 Allogeneic therapy
6.2.1.2.2.1 High potential in disease treatment to ensure demand and development
TABLE 47 REGENERATIVE MEDICINE MARKET FOR ALLOGENEIC THERAPY, BY REGION, 2021–2028 (USD MILLION)
TABLE 48 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR ALLOGENEIC THERAPY, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 49 EUROPE: REGENERATIVE MEDICINE MARKET FOR ALLOGENEIC THERAPY, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 50 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR ALLOGENEIC THERAPY, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 51 LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR ALLOGENEIC THERAPY, BY COUNTRY, 2021–2028 (USD MILLION)
6.2.2 CELL-BASED IMMUNOTHERAPY
6.2.2.1 Growing adoption of T-cell therapy in cancer treatment to support market growth
TABLE 52 REGENERATIVE MEDICINE MARKET FOR CELL-BASED IMMUNOTHERAPY, BY REGION, 2021–2028 (USD MILLION)
TABLE 53 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR CELL-BASED IMMUNOTHERAPY, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 54 EUROPE: REGENERATIVE MEDICINE MARKET FOR CELL-BASED IMMUNOTHERAPY, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 55 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR CELL-BASED IMMUNOTHERAPY, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 56 LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR CELL-BASED IMMUNOTHERAPY, BY COUNTRY, 2021–2028 (USD MILLION)
6.3 GENE THERAPY
6.3.1 STRONG PRODUCT PIPELINE DUE TO BROADENING APPLICATIONS IN DISEASE TREATMENT TO DRIVE MARKET
TABLE 57 APPROVED GENE THERAPIES, 2022
TABLE 58 REGENERATIVE MEDICINE MARKET FOR GENE THERAPY, BY REGION, 2021–2028 (USD MILLION)
TABLE 59 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR GENE THERAPY, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 60 EUROPE: REGENERATIVE MEDICINE MARKET FOR GENE THERAPY, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 61 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR GENE THERAPY, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 62 LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR GENE THERAPY, BY COUNTRY, 2021–2028 (USD MILLION)
6.4 TISSUE ENGINEERING
6.4.1 HIGH DEMAND FOR TISSUE ENGINEERING PRODUCTS IN DERMATOLOGY & WOUND CARE APPLICATIONS TO DRIVE MARKET
TABLE 63 REGENERATIVE MEDICINE MARKET FOR TISSUE ENGINEERING, BY REGION, 2021–2028 (USD MILLION)
TABLE 64 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR TISSUE ENGINEERING, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 65 EUROPE: REGENERATIVE MEDICINE MARKET FOR TISSUE ENGINEERING, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 66 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR TISSUE ENGINEERING, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 67 LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR TISSUE ENGINEERING, BY COUNTRY, 2021–2028 (USD MILLION)
7 REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA
7.1 INTRODUCTION
TABLE 68 NUMBER OF CLINICAL TRIALS FOR REGENERATIVE MEDICINE PRODUCTS, BY THERAPEUTIC AREA, 2021 VS. 2022
TABLE 69 REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
7.2 ONCOLOGY
7.2.1 INCREASING STEM CELL TRANSPLANTS TO DRIVE MARKET
TABLE 70 INDICATIVE LIST OF COMMERCIALIZED REGENERATIVE CELL THERAPIES FOR ONCOLOGY APPLICATIONS
TABLE 71 REGENERATIVE MEDICINE MARKET FOR ONCOLOGY, BY REGION, 2021–2028 (USD MILLION)
TABLE 72 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR ONCOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 73 EUROPE: REGENERATIVE MEDICINE MARKET FOR ONCOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 74 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR ONCOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 75 LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR ONCOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
7.3 MUSCULOSKELETAL DISORDERS
7.3.1 RISING RESEARCH ON MUSCULOSKELETAL REGENERATION AND PREVALENCE OF ORTHOPEDIC DISORDERS TO DRIVE MARKET
TABLE 76 REGENERATIVE MEDICINE MARKET FOR MUSCULOSKELETAL DISORDERS, BY REGION, 2021–2028 (USD MILLION)
TABLE 77 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR MUSCULOSKELETAL DISORDERS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 78 EUROPE: REGENERATIVE MEDICINE MARKET FOR MUSCULOSKELETAL DISORDERS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 79 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR MUSCULOSKELETAL DISORDERS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 80 LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR MUSCULOSKELETAL DISORDERS, BY COUNTRY, 2021–2028 (USD MILLION)
7.4 DERMATOLOGY & WOUND CARE
7.4.1 RISING USE OF WOUND CARE BIOLOGICS TO DRIVE MARKET
TABLE 81 INDICATIVE LIST OF REGENERATIVE MEDICINE PRODUCTS COMMERCIALIZED FOR TREATMENT OF ACUTE & CHRONIC WOUNDS
TABLE 82 REGENERATIVE MEDICINE MARKET FOR DERMATOLOGY & WOUND CARE, BY REGION, 2021–2028 (USD MILLION)
TABLE 83 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR DERMATOLOGY & WOUND CARE, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 84 EUROPE: REGENERATIVE MEDICINE MARKET FOR DERMATOLOGY & WOUND CARE, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 85 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR DERMATOLOGY & WOUND CARE, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 86 LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR DERMATOLOGY & WOUND CARE, BY COUNTRY, 2021–2028 (USD MILLION)
7.5 CARDIOVASCULAR DISEASES
7.5.1 INCREASING USE OF MSCS FOR CLINICAL RESEARCH ON IHD TO SUPPORT MARKET GROWTH
TABLE 87 REGENERATIVE MEDICINE MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2021–2028 (USD MILLION)
TABLE 88 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 89 EUROPE: REGENERATIVE MEDICINE MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 90 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 91 LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)
7.6 OPHTHALMOLOGY
7.6.1 REGENERATION OF EYE TISSUES FOR AMD TO SUPPORT MARKET GROWTH
TABLE 92 LIST OF PIPELINE PRODUCTS FOR REGENERATIVE MEDICINE IN OPHTHALMOLOGY
TABLE 93 REGENERATIVE MEDICINE MARKET FOR OPHTHALMOLOGY, BY REGION, 2021–2028 (USD MILLION)
TABLE 94 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR OPHTHALMOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 95 EUROPE: REGENERATIVE MEDICINE MARKET FOR OPHTHALMOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 96 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR OPHTHALMOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 97 LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR OPHTHALMOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
7.7 NEUROLOGY
7.7.1 GROWING NUMBER OF GENE THERAPY PRODUCTS APPROVED FOR NEUROLOGICAL DISEASE TREATMENT TO DRIVE MARKET GROWTH
TABLE 98 REGENERATIVE MEDICINE MARKET FOR NEUROLOGY, BY REGION, 2021–2028 (USD MILLION)
TABLE 99 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR NEUROLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 100 EUROPE: REGENERATIVE MEDICINE MARKET FOR NEUROLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 101 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR NEUROLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 102 LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR NEUROLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
7.8 OTHER THERAPEUTIC AREAS
TABLE 103 REGENERATIVE MEDICINE MARKET FOR OTHER THERAPEUTIC AREAS, BY REGION, 2021–2028 (USD MILLION)
TABLE 104 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 105 EUROPE: REGENERATIVE MEDICINE MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 106 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 107 LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2021–2028 (USD MILLION)
8 REGENERATIVE MEDICINE MARKET, BY REGION
8.1 INTRODUCTION
FIGURE 27 NUMBER OF PLAYERS IN REGENERATIVE MEDICINE MARKET, BY REGION, 2020–2022
TABLE 108 NUMBER OF CLINICAL TRIALS FOR REGENERATIVE MEDICINE (2022)
TABLE 109 REGENERATIVE MEDICINE MARKET, BY REGION, 2021–2028 (USD MILLION)
8.2 NORTH AMERICA
FIGURE 28 NORTH AMERICA: REGENERATIVE MEDICINE MARKET SNAPSHOT
TABLE 110 NORTH AMERICA: REGENERATIVE MEDICINE MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 111 NORTH AMERICA: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 112 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)
TABLE 113 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)
TABLE 114 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 115 NORTH AMERICA: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
8.2.1 US
8.2.1.1 Rising number of pipeline products for regenerative medicine to drive market
TABLE 116 US: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 117 US: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)
TABLE 118 US: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)
TABLE 119 US: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 120 US: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
8.2.2 CANADA
8.2.2.1 Rising government initiatives for regenerative medicine research to drive market
TABLE 121 CANADA: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 122 CANADA: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)
TABLE 123 CANADA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)
TABLE 124 CANADA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 125 CANADA: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
8.2.3 NORTH AMERICA: RECESSION IMPACT
8.3 EUROPE
TABLE 126 EUROPE: REGENERATIVE MEDICINE MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 127 EUROPE: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 128 EUROPE: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)
TABLE 129 EUROPE: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)
TABLE 130 EUROPE: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 131 EUROPE: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
8.3.1 GERMANY
8.3.1.1 Rising focus on clinical research and patent approvals to drive market
TABLE 132 GERMANY: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 133 GERMANY: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)
TABLE 134 GERMANY: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)
TABLE 135 GERMANY: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 136 GERMANY: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
8.3.2 UK
8.3.2.1 Incorporating regenerative medicine into commercial healthcare services under NHS to drive market
TABLE 137 UK: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 138 UK: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)
TABLE 139 UK: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)
TABLE 140 UK: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 141 UK: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
8.3.3 FRANCE
8.3.3.1 Structured regulatory framework to drive regenerative medicine product pipeline
TABLE 142 FRANCE: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 143 FRANCE: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)
TABLE 144 FRANCE: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)
TABLE 145 FRANCE: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 146 FRANCE: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
8.3.4 ITALY
8.3.4.1 Rising prevalence of neurological and cardiovascular disorders to drive market
TABLE 147 ITALY: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 148 ITALY: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)
TABLE 149 ITALY: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)
TABLE 150 ITALY: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 151 ITALY: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
8.3.5 SPAIN
8.3.5.1 Favorable regulatory environment to drive product pipeline
TABLE 152 SPAIN: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 153 SPAIN: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)
TABLE 154 SPAIN: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)
TABLE 155 SPAIN: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 156 SPAIN: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
8.3.6 REST OF EUROPE
TABLE 157 REST OF EUROPE: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 158 REST OF EUROPE: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)
TABLE 159 REST OF EUROPE: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)
TABLE 160 REST OF EUROPE: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 161 REST OF EUROPE: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
8.3.7 EUROPE: RECESSION IMPACT
8.4 ASIA PACIFIC
FIGURE 29 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET SNAPSHOT
TABLE 162 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 163 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 164 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)
TABLE 165 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)
TABLE 166 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 167 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
8.4.1 CHINA
8.4.1.1 Favorable government support for development of regenerative medicine to drive market
TABLE 168 CHINA: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 169 CHINA: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)
TABLE 170 CHINA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)
TABLE 171 CHINA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 172 CHINA: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
8.4.2 JAPAN
8.4.2.1 Regulatory amendments to pharmaceutical legislation to drive commercialization of therapies
TABLE 173 JAPAN: REGENERATIVE MEDICINE MARKET, BY PRODUCT,
2021–2028 (USD MILLION)
TABLE 174 JAPAN: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)
TABLE 175 JAPAN: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)
TABLE 176 JAPAN: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 177 JAPAN: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA,
2021–2028 (USD MILLION)
8.4.3 INDIA
8.4.3.1 Introduction of novel therapies for CVD and cancer to support market growth
TABLE 178 INDIA: REGENERATIVE MEDICINE MARKET, BY PRODUCT,
2021–2028 (USD MILLION)
TABLE 179 INDIA: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)
TABLE 180 INDIA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)
TABLE 181 INDIA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 182 INDIA: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
8.4.4 SOUTH KOREA
8.4.4.1 Strong research base and availability of funds to support market growth
TABLE 183 SOUTH KOREA: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 184 SOUTH KOREA: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)
TABLE 185 SOUTH KOREA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)
TABLE 186 SOUTH KOREA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 187 SOUTH KOREA: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
8.4.5 AUSTRALIA
8.4.5.1 Increasing incidence of sports injuries to support market growth
TABLE 188 AUSTRALIA: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 189 AUSTRALIA: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)
TABLE 190 AUSTRALIA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)
TABLE 191 AUSTRALIA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 192 AUSTRALIA: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
8.4.6 REST OF ASIA PACIFIC
TABLE 193 REST OF ASIA PACIFIC: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 194 REST OF ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)
TABLE 195 REST OF ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)
TABLE 196 REST OF ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 197 REST OF ASIA PACIFIC: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
8.4.7 ASIA PACIFIC: RECESSION IMPACT
8.5 LATIN AMERICA
TABLE 198 LATIN AMERICA: REGENERATIVE MEDICINE MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 199 LATIN AMERICA: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 200 LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)
TABLE 201 LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)
TABLE 202 LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 203 LATIN AMERICA: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
8.5.1 BRAZIL
8.5.1.1 Gradual increase in pharmaceutical R&D to support market growth
TABLE 204 BRAZIL: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 205 BRAZIL: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)
TABLE 206 BRAZIL: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)
TABLE 207 BRAZIL: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 208 BRAZIL: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
8.5.2 REST OF LATIN AMERICA
TABLE 209 REST OF LATIN AMERICA: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 210 REST OF LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)
TABLE 211 REST OF LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)
TABLE 212 REST OF LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 213 REST OF LATIN AMERICA: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
8.5.3 LATIN AMERICA: RECESSION IMPACT
8.6 MIDDLE EAST
8.6.1 GROWING FOCUS ON GENETIC MEDICINE DEVELOPMENT PROJECTS TO DRIVE MARKET GROWTH IN COMING YEARS
TABLE 214 MIDDLE EAST: REGENERATIVE MEDICINE MARKET, BY PRODUCT,
2021–2028 (USD MILLION)
TABLE 215 MIDDLE EAST: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)
TABLE 216 MIDDLE EAST: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)
TABLE 217 MIDDLE EAST: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 218 MIDDLE EAST: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
8.6.2 MIDDLE EAST: RECESSION IMPACT
8.7 AFRICA
8.7.1 GROWING COLLABORATIONS TO SUPPORT GROWTH IN COMING YEARS
TABLE 219 AFRICA: REGENERATIVE MEDICINE MARKET, BY PRODUCT,
2021–2028 (USD MILLION)
TABLE 220 AFRICA: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)
TABLE 221 AFRICA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY,
BY TYPE, 2021–2028 (USD MILLION)
TABLE 222 AFRICA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 223 AFRICA: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
8.7.2 AFRICA: RECESSION IMPACT
9 COMPETITIVE LANDSCAPE
9.1 INTRODUCTION
9.2 RIGHT-TO-WIN APPROACHES ADOPTED BY KEY PLAYERS
TABLE 224 REGENERATIVE MEDICINE MARKET: STRATEGIES ADOPTED BY KEY PLAYERS
9.3 REVENUE SHARE ANALYSIS
FIGURE 30 REVENUE ANALYSIS OF KEY PLAYERS (2020–2022)
9.4 MARKET SHARE ANALYSIS
FIGURE 31 MARKET SHARE ANALYSIS OF KEY PLAYERS (2022)
TABLE 225 REGENERATIVE MEDICINE MARKET: DEGREE OF COMPETITION
9.5 COMPANY EVALUATION MATRIX
9.5.1 STARS
9.5.2 EMERGING LEADERS
9.5.3 PERVASIVE PLAYERS
9.5.4 PARTICIPANTS
FIGURE 32 REGENERATIVE MEDICINE MARKET: COMPANY EVALUATION MATRIX, 2022
9.5.5 COMPANY FOOTPRINT ANALYSIS
TABLE 226 REGENERATIVE MEDICINE MARKET: PRODUCT FOOTPRINT ANALYSIS OF KEY PLAYERS
TABLE 227 REGENERATIVE MEDICINE MARKET: REGIONAL FOOTPRINT ANALYSIS OF KEY PLAYERS
9.6 START-UP/SME EVALUATION MATRIX
9.6.1 PROGRESSIVE COMPANIES
9.6.2 RESPONSIVE COMPANIES
9.6.3 DYNAMIC COMPANIES
9.6.4 STARTING BLOCKS
FIGURE 33 REGENERATIVE MEDICINE MARKET: START-UP/SME EVALUATION MATRIX, 2022
9.6.5 COMPETITIVE BENCHMARKING
TABLE 228 REGENERATIVE MEDICINE MARKET: DETAILED LIST OF KEY START-UP/SME PLAYERS
TABLE 229 REGENERATIVE MEDICINE MARKET: COMPETITIVE BENCHMARKING OF START-UP/SME PLAYERS
9.7 COMPETITIVE SCENARIO & TRENDS
9.7.1 PRODUCT LAUNCHES
TABLE 230 REGENERATIVE MEDICINE MARKET: PRODUCT APPROVALS/LAUNCHES, JANUARY 2020 TO DECEMBER 2023
9.7.2 DEALS
TABLE 231 REGENERATIVE MEDICINE MARKET: DEALS, JANUARY 2020 TO DECEMBER 2023
9.7.3 OTHER DEVELOPMENTS
TABLE 232 REGENERATIVE MEDICINE MARKET: OTHER DEVELOPMENTS, JANUARY 2020 TO DECEMBER 2023
10 COMPANY PROFILES
10.1 KEY MARKET PLAYERS
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
10.1.1 NOVARTIS AG
TABLE 233 NOVARTIS AG: COMPANY OVERVIEW
FIGURE 34 NOVARTIS AG: COMPANY SNAPSHOT (2022)
10.1.2 BIOGEN INC.
TABLE 234 BIOGEN INC.: COMPANY OVERVIEW
FIGURE 35 BIOGEN INC.: COMPANY SNAPSHOT (2022)
10.1.3 GILEAD SCIENCES, INC.
TABLE 235 GILEAD SCIENCES, INC.: COMPANY OVERVIEW
FIGURE 36 GILEAD SCIENCES, INC.: COMPANY SNAPSHOT (2022)
10.1.4 SAREPTA THERAPEUTICS, INC.
TABLE 236 SAREPTA THERAPEUTICS, INC.: COMPANY OVERVIEW
FIGURE 37 SAREPTA THERAPEUTICS: COMPANY SNAPSHOT (2022)
10.1.5 AMGEN, INC.
TABLE 237 AMGEN, INC.: COMPANY OVERVIEW
FIGURE 38 AMGEN, INC.: COMPANY SNAPSHOT (2022)
10.1.6 SMITH+NEPHEW
TABLE 238 SMITH+NEPHEW: COMPANY OVERVIEW
FIGURE 39 SMITH+NEPHEW: COMPANY SNAPSHOT (2022)
10.1.7 MEDIPOST CO., LTD.
TABLE 239 MEDIPOST CO., LTD.: COMPANY OVERVIEW
FIGURE 40 MEDIPOST CO., LTD.: COMPANY SNAPSHOT
10.1.8 JCR PHARMACEUTICALS CO., LTD.
TABLE 240 JCR PHARMACEUTICALS CO., LTD.: COMPANY OVERVIEW
FIGURE 41 JCR PHARMACEUTICALS CO., LTD.: COMPANY SNAPSHOT (2022)
10.1.9 TAKEDA PHARMACEUTICAL COMPANY LIMITED
TABLE 241 TAKEDA PHARMACEUTICAL COMPANY LIMITED: COMPANY OVERVIEW
FIGURE 42 TAKEDA PHARMACEUTICAL COMPANY LIMITED: COMPANY SNAPSHOT (2022)
10.1.10 CORESTEM, INC.
TABLE 242 CORESTEM, INC.: COMPANY OVERVIEW
FIGURE 43 CORESTEM, INC.: COMPANY SNAPSHOT (2021)
10.1.11 VERICEL CORPORATION
TABLE 243 VERICEL CORPORATION: COMPANY OVERVIEW
FIGURE 44 VERICEL CORPORATION: COMPANY SNAPSHOT (2022)
10.1.12 MIMEDX GROUP, INC.
TABLE 244 MIMEDX GROUP, INC.: COMPANY OVERVIEW
FIGURE 45 MIMEDX GROUP, INC.: COMPANY SNAPSHOT (2022)
10.1.13 ORGANOGENESIS INC.
TABLE 245 ORGANOGENESIS INC.: COMPANY OVERVIEW
FIGURE 46 ORGANOGENESIS INC.: COMPANY SNAPSHOT (2022)
10.1.14 MEDTRONIC
TABLE 246 MEDTRONIC: COMPANY OVERVIEW
FIGURE 47 MEDTRONIC: COMPANY SNAPSHOT (2022)
10.1.15 BRISTOL-MYERS SQUIBB COMPANY
TABLE 247 BRISTOL-MYERS SQUIBB COMPANY: COMPANY OVERVIEW
FIGURE 48 BRISTOL-MYERS SQUIBB COMPANY: COMPANY SNAPSHOT (2022)
10.2 OTHER PLAYERS
10.2.1 ORTHOCELL LTD.
TABLE 248 ORTHOCELL LTD.: COMPANY OVERVIEW
10.2.2 MESOBLAST LTD.
TABLE 249 MESOBLAST LTD.: COMPANY OVERVIEW
10.2.3 BIORESTORATIVE THERAPIES, INC.
TABLE 250 BIORESTORATIVE THERAPIES, INC.: COMPANY OVERVIEW
10.2.4 PLURISTEM THERAPEUTICS INC.
TABLE 251 PLURISTEM THERAPEUTICS INC.: COMPANY OVERVIEW
10.2.5 TEGOSCIENCE
TABLE 252 TEGOSCIENCE: COMPANY OVERVIEW
10.2.6 ANTEROGEN.CO.,LTD.
TABLE 253 ANTEROGEN.CO.,LTD.: COMPANY OVERVIEW
10.2.7 BLUEBIRD BIO, INC.
TABLE 254 BLUEBIRD BIO, INC.: COMPANY OVERVIEW
10.2.8 STEMPEUTICS RESEARCH PVT. LTD.
TABLE 255 STEMPEUTICS RESEARCH PVT. LTD.: COMPANY OVERVIEW
10.2.9 SIBIONO GENETECH CO. LTD.
TABLE 256 SIBIONO GENETECH CO. LTD.: COMPANY OVERVIEW
10.2.10 ASPECT BIOSYSTEMS
TABLE 257 ASPECT BIOSYSTEMS: COMPANY OVERVIEW
TABLE 258 ATHERSYS, INC.: COMPANY OVERVIEW
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
11 APPENDIX
11.1 DISCUSSION GUIDE
11.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
11.3 CUSTOMIZATION OPTIONS
11.4 RELATED REPORTS
11.5 AUTHOR DETAILS
